CA
NZ
UK
AU
IND
US
…
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cosciens Biopharma Inc. is a Nasdaq-listed clinical-stage biopharmaceutical company with limited public disclosure that appears focused on advancing early-stage therapeutic candidates and building intellectual property. Long-term growth drivers may include favorable clinical results, regulatory approvals, strategic partnerships and successful commercialization, which could support value appreciation for investors.
Key investment risks include high probability of clinical and regulatory setbacks, no meaningful revenue and ongoing financing needs that could dilute shareholders, together with thin public information that complicates independent assessment.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -15.22M | -4.37M | 4.53M | 2.59M | 1.46M |
| Net income | -15.31M | -3.48M | 3.45M | 2.64M | 1.46M |
| Selling general administrative | 10.45M | 5.59M | 2.73M | 2.54M | 2.57M |
| Selling and marketing expenses | - | 0.03M | 0.02M | 0.04M | 0.09M |
| Gross profit | 6.80M | 2.94M | 8.56M | 8.21M | 5.98M |
| Reconciled depreciation | 1.61M | 1.44M | 1.47M | 1.48M | 1.44M |
| Ebit | -15.10M | -4.23M | 4.67M | 2.71M | 1.59M |
| Ebitda | -13.49M | -2.79M | 6.14M | 4.18M | 3.04M |
| Depreciation and amortization | 1.61M | 1.44M | 1.47M | 1.48M | 1.44M |
| Operating income | -26.28M | -4.63M | 4.32M | 2.43M | 1.66M |
| Other operating expenses | 40.06M | 11.77M | 10.25M | 11.06M | 10.20M |
| Interest expense | 0.13M | 0.14M | 0.14M | 0.12M | 0.14M |
| Tax provision | 0.08M | -0.89M | 1.08M | -0.05M | 0.00M |
| Interest income | 0.44M | 0.06M | 0.14M | - | - |
| Net interest income | 0.31M | -0.08M | 0.00M | -0.16M | -0.18M |
| Income tax expense | 0.08M | -0.89M | 1.08M | -0.05M | 0.42M |
| Total revenue | 13.78M | 7.14M | 14.57M | 13.49M | 11.86M |
| Total operating expenses | 33.08M | 7.57M | 4.24M | 5.78M | 4.32M |
| Cost of revenue | 6.98M | 4.21M | 6.02M | 5.28M | 5.88M |
| Total other income expense net | 11.06M | 0.26M | 0.21M | 0.16M | -0.20M |
| Net income from continuing ops | -15.31M | -3.48M | 3.45M | 2.64M | 1.46M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 35.07M | 23.75M | 27.80M | 24.35M | 22.92M |
| Intangible assets | - | 0.01M | 0.01M | 0.01M | 0.01M |
| Other current assets | 2.43M | 0.29M | 0.10M | 0.15M | 0.27M |
| Total liab | 21.91M | 2.71M | 4.01M | 2.61M | 3.85M |
| Total stockholder equity | 13.16M | 21.04M | 23.79M | 21.74M | 19.06M |
| Other current liab | 4.29M | 0.73M | 1.67M | 1.13M | 1.31M |
| Common stock | 22.49M | 13.52M | 12.30M | 12.99M | 12.95M |
| Capital stock | 22.49M | 16.72M | 16.69M | 16.56M | 16.51M |
| Retained earnings | -12.11M | 4.36M | 8.02M | 5.08M | 2.44M |
| Other assets | - | - | - | 0.00M | 0.00M |
| Cash | 16.39M | 6.68M | 10.18M | 6.10M | 4.21M |
| Total current liabilities | 7.22M | 1.31M | 7.04M | 7.76M | 4.74M |
| Current deferred revenue | 0.12M | - | 2.95M | 4.81M | 2.19M |
| Net debt | -14.08M | -4.98M | -8.25M | -4.03M | -1.88M |
| Short term debt | 0.27M | 0.60M | 0.39M | 0.36M | 0.25M |
| Short long term debt | - | - | - | - | 0.07M |
| Short long term debt total | 2.31M | 1.70M | 1.93M | 2.08M | 2.33M |
| Other stockholder equity | 4.27M | 3.16M | 3.47M | 3.67M | 3.67M |
| Total current assets | 23.98M | 11.27M | 15.17M | 9.73M | 7.10M |
| Net receivables | 2.47M | 0.29M | 2.13M | 1.68M | 1.66M |
| Inventory | 2.69M | 4.01M | 2.77M | 0.07M | 0.95M |
| Accounts payable | 2.41M | 0.28M | - | - | - |
| Accumulated other comprehensive income | -1.48M | 4.35M | 4.12M | 4.40M | 11.36M |
| Non currrent assets other | 0.12M | 0.75M | 0.69M | 0.66M | 0.54M |
| Non current assets total | 11.09M | 12.48M | 12.63M | 14.62M | 15.82M |
| Capital lease obligations | 2.31M | 2.25M | 2.62M | 2.65M | 2.90M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 25.08M | -0.73M | -0.39M | -0.79M | -0.48M |
| Total cashflows from investing activities | 25.08M | -0.73M | -0.30M | -0.62M | -0.38M |
| Total cash from financing activities | -0.59M | -0.36M | -0.27M | 50.59M | 21.55M |
| Net income | -15.31M | -3.48M | 3.45M | 2.64M | 1.46M |
| Change in cash | 9.71M | -3.51M | 4.03M | 1.89M | 2.75M |
| Begin period cash flow | 6.68M | 10.19M | 6.16M | 4.21M | 1.46M |
| End period cash flow | 16.39M | 6.68M | 10.19M | 6.10M | 4.21M |
| Total cash from operating activities | -14.57M | -2.58M | 5.23M | 2.75M | 3.49M |
| Depreciation | 1.61M | 1.47M | 1.47M | 1.48M | 1.44M |
| Other cashflows from investing activities | 0.21M | -0.01M | - | -0.06M | 0.11M |
| Change to inventory | 1.59M | -1.17M | -1.06M | -0.87M | 1.24M |
| Change to account receivables | -2.42M | 1.79M | -0.62M | -0.14M | 1.24M |
| Other cashflows from financing activities | -0.01M | 0.01M | 0.06M | 0.02M | 0.00M |
| Capital expenditures | 1.16M | 0.72M | 0.01M | 0.56M | 0.49M |
| Change in working capital | -1.67M | 0.06M | -0.94M | -1.16M | 0.47M |
| Stock based compensation | 0.46M | 0.19M | 0.07M | 0.01M | 0.11M |
| Other non cash items | 0.27M | 0.10M | 0.10M | 0.01M | 0.02M |
| Free cash flow | -15.73M | -3.30M | 4.92M | 2.20M | 3.01M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Giuliano La Fratta | Senior VP of Finance & CFO | NA |
| Mr. Michel Regnier P. Eng. | Senior VP of Technical operations, MD of Ceapro Inc. & CTO | NA |
| Dr. Michael Teifel Ph.D. | Senior Vice President of GmbH & Chief Scientific Officer | NA |
| Dr. Matthias Gerlach | Senior Vice President Manufacturing and Supply Chain & Head of Production | NA |
| Ms. Anna Elizabeth Biehn | Chief Executive Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...